期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 41, 期 7, 页码 464-474出版社
CELL PRESS
DOI: 10.1016/j.tips.2020.04.005
关键词
-
资金
- National Natural Science Foundation of China [81925012, 81870990, 31961130379]
- Newton Advanced Fellowship from Academy of Medical Sciences [NAF\R1\191045]
Traditional drug discovery focuses on identifying direct inhibitors of target proteins. This typically relies on a measurable biochemical readout and accessible binding sites whose occupancy influences the function of the target protein. These requirements preclude many disease-causing proteins from being 'druggable' targets, and these proteins are categorized as 'undruggable'. The proteolysis-targeting chimera (PROTAC) technology provides powerful tools to degrade these undruggable targets and has become a promising approach for drug discovery. However, the PROTAC technology has some limitations, and emerging new degrader technologies may greatly broaden the spectrum of targets that could be selectively degraded by harnessing a second major degradation pathway in cells. We review key emerging technologies that exploit the lysosomal degradation pathway and discuss their potential applications and limitations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据